U.S. markets open in 7 hours 35 minutes
  • S&P Futures

    3,755.75
    -33.75 (-0.89%)
     
  • Dow Futures

    30,519.00
    -262.00 (-0.85%)
     
  • Nasdaq Futures

    11,414.75
    -114.75 (-1.00%)
     
  • Russell 2000 Futures

    1,686.70
    -21.30 (-1.25%)
     
  • Crude Oil

    104.85
    -0.91 (-0.86%)
     
  • Gold

    1,796.50
    -10.80 (-0.60%)
     
  • Silver

    19.89
    -0.47 (-2.29%)
     
  • EUR/USD

    1.0469
    -0.0014 (-0.14%)
     
  • 10-Yr Bond

    2.9720
    0.0000 (0.00%)
     
  • Vix

    28.71
    +0.55 (+1.95%)
     
  • GBP/USD

    1.2133
    -0.0043 (-0.35%)
     
  • USD/JPY

    135.0120
    -0.7160 (-0.53%)
     
  • BTC-USD

    19,489.58
    -508.78 (-2.54%)
     
  • CMC Crypto 200

    418.46
    -13.01 (-3.02%)
     
  • FTSE 100

    7,169.28
    -143.04 (-1.96%)
     
  • Nikkei 225

    25,890.62
    -502.42 (-1.90%)
     

We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for PMV Pharmaceuticals (NASDAQ:PMVP) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

See our latest analysis for PMV Pharmaceuticals

When Might PMV Pharmaceuticals Run Out Of Money?

A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. In March 2022, PMV Pharmaceuticals had US$283m in cash, and was debt-free. Looking at the last year, the company burnt through US$54m. So it had a cash runway of about 5.3 years from March 2022. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is PMV Pharmaceuticals' Cash Burn Changing Over Time?

PMV Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 42%, which suggests that management are increasing investment in future growth, but not too quickly. That's not necessarily a bad thing, but investors should be mindful of the fact that will shorten the cash runway. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.

How Hard Would It Be For PMV Pharmaceuticals To Raise More Cash For Growth?

While PMV Pharmaceuticals does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Since it has a market capitalisation of US$699m, PMV Pharmaceuticals' US$54m in cash burn equates to about 7.7% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

So, Should We Worry About PMV Pharmaceuticals' Cash Burn?

As you can probably tell by now, we're not too worried about PMV Pharmaceuticals' cash burn. For example, we think its cash runway suggests that the company is on a good path. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, PMV Pharmaceuticals has 4 warning signs (and 2 which are concerning) we think you should know about.

Of course PMV Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.